| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.22902 |
| P698 | PubMed publication ID | 17628484 |
| P2093 | author name string | Jennifer J Knox | |
| Gregory R Pond | |||
| Rachel P Riechelmann | |||
| Sheray N Chin | |||
| Carol A Townsley | |||
| P2860 | cites work | Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas | Q44118434 |
| Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer | Q44508387 | ||
| Gallbladder cancer, a different disease that needs individual trials | Q46761599 | ||
| Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer | Q72821837 | ||
| Worldwide trends in mortality from biliary tract malignancies | Q21093310 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer | Q33214444 | ||
| A phase II study of gemcitabine in gallbladder carcinoma | Q33340368 | ||
| Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma | Q33343774 | ||
| Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial | Q33359839 | ||
| Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases | Q33363103 | ||
| A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma | Q33363963 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. | Q33369276 | ||
| Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma | Q33370799 | ||
| Cholangiocarcinoma. | Q33990595 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. | Q34554801 | ||
| Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial | Q36624106 | ||
| P433 | issue | 6 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| capecitabine | Q420207 | ||
| P304 | page(s) | 1307-1312 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer | |
| P478 | volume | 110 |
| Q84325484 | A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management |
| Q33404952 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study |
| Q36459140 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. |
| Q89326683 | A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin |
| Q42004327 | Accomplishments in 2007 in the management of hepatobiliary cancers. |
| Q38650019 | Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers |
| Q43055996 | Advanced ampullary carcinoma showing complete response to S-1: report of a case |
| Q26822703 | Advances in systemic therapy for advanced pancreatobiliary malignancies |
| Q37614142 | Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer |
| Q33977171 | Chemotherapy and targeted therapy for gall bladder cancer |
| Q33593207 | Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function |
| Q92283408 | Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy |
| Q39380445 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? |
| Q35583920 | Current management of gallbladder carcinoma |
| Q37138732 | Current status of chemotherapy for the treatment of advanced biliary tract cancer |
| Q37176933 | Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies |
| Q33372792 | EGFR expression in gallbladder carcinoma in North America |
| Q43237133 | Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study |
| Q38707983 | Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma |
| Q26784174 | Gallbladder Cancer in the 21st Century |
| Q89767854 | Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease |
| Q33383423 | Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study |
| Q33391003 | Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study |
| Q37765099 | Genetics of biliary tract cancers and emerging targeted therapies |
| Q30300756 | Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades |
| Q37112614 | Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma |
| Q83969569 | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness |
| Q37362900 | Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q34551877 | Systemic Therapy of Cholangiocarcinoma |
| Q33556487 | Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials |
| Q37132750 | Targeted therapy for biliary tract cancer |
| Q30234532 | Targeted therapy in biliary tract cancers-current limitations and potentials in the future |
| Q89533973 | Targeting gallbladder cancer: a pathway based perspective |
| Q37261360 | The role of chemotherapy in biliary tract carcinoma |
Search more.